Work

1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNα2A AND RIBAVIRIN

Year: 2012

Type: article

Source: Journal of Hepatology

DOI: 10.1016/s0168-8278(12)61414-7

Authors: H. Wedemeyer, E. Janczewska, M. Wlodzimierz, C. Stanciu, F. Habersetzer, V. Carreno, A.M. Di Bisceglie, C. Tanasescu, R. Flisiak, M. Romero-Gomez, A. Fich, C. Zemmour, A. Fournillier, P. Zerr, D. Agathon, H. He, J.-Y. Bonnefoy, F. Inchauspe, J.-M. Limacher

Institution: Medizinische Hochschule Hannover

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2042405722

FWCI: 0.804

Cites:

Cited by: 6

Related to: 10